Monday, August 17, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Aug 14, 2026
Capricor soars on plan to amend DMD filing after adcomm setback
background ▾
- •FDA granted Capricor permission to amend its deramiocel application to shift focus from the failed secondary endpoint (cardiomyopathy) to the primary endpoint (upper-limb function), potentially rescuing the program after advisory committee rejection
- •Advisory committee discussion of upper-limb efficacy was described as 'directionally supportive' but with significant uncertainty—experts noted the data is 'fragile' and questioned whether a real effect exists, creating substantial approval risk
- •Watch for: timing of Capricor's amendment submission, FDA's review of 24-month extension data, and the new PDUFA action date; outcome will depend on whether upper-limb function data can satisfy efficacy threshold that cardiomyopathy data failed to meet
Capricor Therapeuticsderamiocel
→ Read original articlePolicy•STAT News•Aug 17, 2026
Opinion: We proved bipartisan health care reform works in North Carolina. Let’s bring it nationwide
background ▾
- •HOP achieved statistically significant Medicaid savings of $164 per person per month after accounting for all program costs—potentially representing billions in savings at scale—by shifting care from emergency departments to community-based social services
- •The rigorous 31-month evaluation by University of North Carolina showed sustained improvements in health outcomes, reduced hospitalizations, and decreased food insecurity and housing instability among participants, with 90% reporting health improvements
- •Watch for Congressional action on codifying Medicaid pathways for social determinants of health funding; North Carolina's bipartisan success and legislative renewal in July 2024 may accelerate broader policy adoption and reimbursement models that incentivize preventive social services
Policy•STAT News•Aug 17, 2026
Opinion: Paid paternity leave is pediatric preventive care
background ▾
- •The opinion reframes paid paternity leave as a pediatric preventive care intervention rather than labor policy, leveraging neuroscience evidence of father-child bonding benefits and measurable neurobiological changes in fathers during early caregiving
Policy•Fierce Biotech•Aug 14, 2026
Chutes & Ladders—Former Legend CEO lands at K2
background ▾
- •This is a routine personnel roundup column with no material clinical, regulatory, or market-moving developments
K2 TherapeuticsLegend BiotechTanai TherapeuticsCarvyktificerafusp alfa
→ Read original articlePolicy•Endpoints News•Aug 15, 2026
Trump’s MMR order; LSD drug clears Phase 3 test; and more
background ▾
- •Trump administration issued an MMR-related order that could affect vaccination policy or pharma market access
- •An LSD-based drug candidate has successfully completed Phase 3 clinical testing, advancing psychedelic therapeutics toward potential regulatory submission
- •Monitor for clarification on the scope and implementation timeline of the MMR order and the LSD drug candidate's regulatory pathway
LSD
→ Read original articleMarket Access
Market Access•Fierce Biotech•Aug 14, 2026
Skye and Redx form new entity with $125M to advance fibrosis assets
background ▾
- •RXC008 received FDA Fast Track designation in January and is positioned as potentially the first-in-class pan-ROCK inhibitor for fibrostenotic Crohn's disease, addressing a major unmet medical need where current standard-of-care involves surgical intervention
- •The $125M financing, led by established investors including Abingworth and 5AM Ventures, provides adequate runway through 2029 to generate Phase 2 topline data in H2 2028, a critical value inflection point
- •Watch for Phase 2 efficacy and safety data on RXC008 in H2 2028; success could unlock partnerships or accelerated development pathways given the unmet need and Fast Track status
Skye BioscienceRedx PharmaFibrx TherapeuticsRXC008nimacimabsemaglutide
→ Read original articleMarket Access•Endpoints News•Aug 14, 2026
Redx tries again at reverse merger, with Skye this time, as route gains steam
background ▾
- •Redx Pharma is attempting a second reverse merger after 2023 failure, this time with Skye Bioscience as the SPAC partner
Redx PharmaSkye Bioscience
→ Read original articleMarket Access•Fierce Biotech•Aug 14, 2026
‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
background ▾
- •BioCryst is abandoning internal discovery in favor of pure external licensing model, funded by Orladeyo's strong commercial performance and profitability
- •The company previously scrapped avoralstat (DME program) and now closed its entire Discovery Center, signaling major operational restructuring
- •Near-term catalysts include BCX17725 (Netherton syndrome) phase 1 data by end of 2026 and navenibart phase 3 readout in Q3 2027; success of deal sourcing strategy remains uncertain
BioCryst PharmaceuticalsAstria TherapeuticsNeopharmed GentiliOrladeyoavoralstatnavenibart
→ Read original articleMarket Access•Endpoints News•Aug 14, 2026
Biogen's monoclonal antibody felzartamab wins first global approval in China
background ▾
- •Felzartamab achieves first-ever global approval, de-risking the asset and demonstrating regulatory acceptance of its mechanism in multiple myeloma
- •China approval provides early market entry and revenue opportunity in a large, growing oncology market with high unmet need in myeloma
- •Pending regulatory decisions in the US and EU will determine whether China approval signals broader market potential or represents a China-specific win
Biogenfelzartamab
→ Read original articleMarket Access•Endpoints News•Aug 14, 2026
ICER says AstraZeneca’s new blood pressure med isn’t cost-effective
background ▾
- •ICER's negative cost-effectiveness assessment at $10,950/year will create significant headwinds for Baxfendy's market access and payer coverage negotiations
- •AstraZeneca may face pressure to reduce pricing or risk limited formulary inclusion and restricted patient access to the medication
- •Watch for AstraZeneca's response—whether the company challenges ICER's analysis, submits additional data, or initiates price negotiations with major payers
AstraZenecaICERBaxfendy
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Aug 17, 2026
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
background ▾
- •Volrustomig failed to meet dual primary endpoints for PD-L1-negative NSCLC despite phase 1/2 promise, suggesting bispecific PD-1xCTLA-4 approach does not overcome inherent resistance in this population
- •The failure removes a potential differentiator in an area of genuine clinical need; PD-L1-low/negative patients have limited durable responses to current immunotherapies but toxicity limits combination checkpoint inhibitor use
- •Watch for outcomes in ongoing volrustomig trials in cervical cancer, HNSCC, and mesothelioma—and investor reaction to the broader bispecific pipeline, particularly rilvegostomig (PD-1xTIGIT), which analysts already view skeptically
AstraZenecaMerck & Co.Bristol Myers SquibbvolrustomigKeytrudaYervoy
→ Read original articleClinical Trials•Endpoints News•Aug 14, 2026
Abcuro gets $66M for Phase 3 in muscle-weakening condition
background ▾
- •Abcuro raised $66M to fund Phase 3 development after pivoting indication following prior clinical failure
- •The funding decision indicates potential clinical promise in an alternative indication despite earlier setback
Abcuro
→ Read original article